Lasa Supergenerics Limited

Stock Opportunities Untested - but worth a good look
179

Lasa concall Updates:

  1. Company guided for 22-25% growth going ahead keeping Unit-4 into consideration
  2. After promoters interse transfer Omkar will hold 36.5% of company and 10% still be with OSCL which they are gradually selling.
  3. Q2 profitability impacted due to higher prices of raw materials which are crude derivatives
  4. Regarding coming out of T2T segment, there is nothing pending from company side, SEBI will review on quarterly basis
  5. Total debt is 68 cr (LT+ST)
  6. Promoter infusing his own money to pare debt
  7. Export @40% of revenue, No single client is more than 5%
  8. Current rate of depreciation @6cr/quarter will continue and taxes will be normalised from next quarter

Valuations:

Mcap 300cr, Debt 70cr

EV: 370cr

H-1 Ebidta : 31 cr

H-1 PAT: 16cr

Company available at

EV/Ebidta@6

P/E @9

3 Likes
181

Can you please share the report or link @khushi

182

Its already in the thread…please scroll :slightly_smiling_face::slightly_smiling_face:

1 Like
183

last con-call transcript from BSE if anyone interested

http://www.bseindia.com/xml-data/corpfiling/AttachLive/f90549b2-3f16-426a-aefb-931012112e16.pdf

1 Like
184

other current liabilities of 29cr is also Debt.

185

What r the chances of reduce down or increase raw material cost (crude derivative) in coming quarters??

Q2 profit impacted by raw material oil derivative. What kind of oil derivatives used in API. If u compare input cost with peers- NG fine , sequent cost increased by 9% and 6% qoq resp. Whereas in lasa increased by 14%…

1 Like
186

Media Release - FAQ

http://www.bseindia.com/xml-data/corpfiling/AttachLive/7ad57920-c637-4c59-8659-901d4ec3f877.pdf

image
image975×679 92.4 KB

Read more in the attachment

4 Likes
187

Promoter Mr. Omkar H acquires 8 lakh shares from Pravin Herlekar at Rs 142.

http://www.bseindia.com/xml-data/corpfiling/AttachLive/dbea486e-856b-4a5e-9431-2c3b27df2c69.pdf

1 Like
188

Mgmt Interview

189

Board meeting for discussing on matters like Fund raising & reclassification of promoter’s list is Scheduled to be on 6th Jan.
http://www.bseindia.com/xml-data/corpfiling/AttachLive/49f1a7a9-5b44-4629-aed8-21c4b35643df.pdf

190

Is it normal to acquire shares at such lower prices than the current market price?

191

THE price has increased only in last week . THIS is more of a transfer that was talked about in conference call. Both were promoters earlier.

192

My view: We generally see the price in the case of Preferential allotment & warrant. Since this transaction is between the father & son, it should not affect other shareholders.

1 Like
193

The deal and the agreed price is approved as per the SEBI’s Substantial Acquisition of Shares and Takeovers Regulations…so there is no question of any wrongdoing. Also, since the deal happened between two promoters off the market, there would be no material impact on market price besides a few random speculations about the fair price of the stock.

4 Likes
194

New CEP application filed for VET API range of product with EDQM – Europe

Mumbai, January 2, 2018: Lasa Supergenerics Limited, pioneer and amongst the leading player in manufacturing of Veterinary APIs in India through its catalyst chemistry expertise and fully backward integrated unit, announced that the Company has filed new CEP application for VET API product with EDQM (European Directorate for the Quality of Medicines) - Europe.

195

http://www.bseindia.com/xml-data/corpfiling/AttachLive/f54f204a-8c23-4242-90fa-c359524e563b.pdf

196

What I am unable to understand is that they already have a CEP for Fenbendazole that was issued in oct 14. What is this new CEP for? Is it for some new range of products?

197

Does anyone know how T2T group works and when exactly do the reviews happen and therefore when should we look out for a change if it happens?

198

Review happen on Quarterly basis. In my view it is due on 1st Feb

https://www.nseindia.com/products/content/equities/equities/tt_schedule.htm

199

The role of a Certificate of Suitability (CEP) is to certify the compliance of a material with the requirements laid down in the relevant monograph of the European Pharmacopoeia. Active pharmaceutical ingredients for which a Certificate of Suitability has been granted are suitable for use in medicinal products.